CSL Cash Flow from Operating Activities 2017-2024 | CSLLY

CSL cash flow from operating activities for the twelve months ending December 31, 2024 was $6.346B, a 36.53% decline year-over-year.

  • CSL annual cash flow from operating activities for 2024 was $2.764B, a 6.27% increase from 2023.
  • CSL annual cash flow from operating activities for 2023 was $2.601B, a 1.07% decline from 2022.
  • CSL annual cash flow from operating activities for 2022 was $2.629B, a 27.41% decline from 2021.

CSL Cash Flow from Operating Activities 2017-2024 | CSLLY

  • CSL annual cash flow from operating activities for 2024 was $2.764B, a 6.27% increase from 2023.
  • CSL annual cash flow from operating activities for 2023 was $2.601B, a 1.07% decline from 2022.
  • CSL annual cash flow from operating activities for 2022 was $2.629B, a 27.41% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.5B
Amgen (AMGN)$165.9B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$99.6B
GSK (GSK)$78.3B
Regeneron Pharmaceuticals (REGN)$61B
Alnylam Pharmaceuticals (ALNY)$42.8B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.4B
Illumina (ILMN)$17B
Genmab (GMAB)$15.2B
Genmab (GNMSF)$14.9B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.5B
QIAGEN (QGEN)$11.4B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.2B
Bio-Techne Corp (TECH)$9.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B
Regencell Bioscience Holdings (RGC)$7.5B